Table 1 Summary of demographics and clinical information of the patients included in the study.
Characteristics | ||
|---|---|---|
Gender | Value | % |
Male | 30 | 51.7 |
Female | 28 | 48.3 |
Age at surgery (years) | Value | % |
< 65 | 44 | 75.9 |
≥ 65 and < 75 | 8 | 13.8 |
> 75 | 6 | 10.3 |
Metastatic melanoma location | Value | % |
Distant skin site | 10 | 17.2 |
Distant organ | 17 | 29.3 |
Distant lymph node | 28 | 48.3 |
Distant subcutaneous site | 3 | 5.2 |
Metastasis stage | Value | % |
M1a | 8 | 13.8 |
M1b | 8 | 13.8 |
M1c | 42 | 72.4 |
Primary melanoma type | Value | % |
Cutaneous | 46 | 79.3 |
Mucosal | 1 | 1.7 |
Ocular | 2 | 3.4 |
Unknown | 9 | 15.5 |
Treatment | Value | % |
Dacarbazine | 3 | 5.2 |
Dacarbazine, Cisplatin | 54 | 93.1 |
Dacarbazine, Carboplatin | 1 | 1.7 |
Overall survival | t0 = sample collection | t0 = chemotherapy start |
Median (range) in months | 19 (2–126) | 11 (0–87) |
Progression-free survival | t0 = sample collection | t0 = chemotherapy start |
Median (range) in months | 10 (1–100) | 4 (0–83) |
